FUNCTIONAL GENOMICS & DRUG DISCOVERY:
STRATEGIC APPROACHES FOR DECISION MAKINGWhen: June 4 - 5, 2018
Where: Harvard Medical School | Boston
What: 2-day program for science and business leaders involved in drug development
*Discount available for groups of three or more from a single organization
There has been increasing interest and investment in applying genomics and related technologies to drug discovery and development. However, with the exception of a small number of well-known successes, much uncertainty remains about how to best leverage these tools throughout the pharmaceutical value chain.
Led by renowned leaders from industry and academia, this program provides a unique opportunity to delve into the use of genomics in rare and complex diseases, and throughout the drug discovery, development, regulatory, and post-regulatory phases. Pre-work, case-based teaching, and project work will ground insights in real-world applications.
Program Objectives:By the end of the program, participants will be able to:
employ new approaches for leveraging genomic tools to validate targets, streamline clinical trials, decrease late development attrition, and identify patient groups in the marketplace.
apply program concepts to inform decisions about R&D priorities and directions, the evaluation of internal and external opportunities, and strategic thinking.
Program topic areas include:
Applications of genetics in common and rare diseases
Discovery and validation of new targets
Moving from genes to function and phenotypes
Identifying causal biomarkers for clinical development
De-risking development by predicting potential adverse effects
Patient segmentation to streamline clinical trials
Strategic approach to companion diagnostics
Regulatory implications of genetics-informed development
Implications for increased use of genetics for patient-centric R&D
Future state: new technologies and approaches
Faculty: Program faculty are preeminent experts in genomics and drug discovery and development, drawn from industry and academia.
Stanley Shaw, MD, PhD, Faculty Chair
Associate Dean for Executive Education, Harvard Medical School
George M. Church, PhD
Professor of Genetics, Harvard Medical School; Professor of Health Sciences and Technology, Harvard and MIT
Sally John, PhD
Vice President, Translational Biology, Biogen Idec
Sekar Kathiresan, MD
Director, Center for Genomic Medicine, Massachusetts General Hospital; Director, Cardiovascular Disease Initiative, Broad Institute; Associate Professor of Medicine, Harvard Medical School
Robert Plenge, MD, PhD
Vice President, Translational Development, Research & Early Development, Celgene
Ramnik Xavier, MD, PhD
Chief, Gastroenterology Unit, Massachusetts General Hospital; Institute Member, Co-Director of the Infectious Disease and Microbiome Program, Broad Institute; Kurt Isselbacher Professor of Medicine, Harvard Medical School